Hamzei Analytics Financial Network

Our mission is to provide valuable trading insights to advanced traders for analysis of mass behavior in the equity, bond, commodity and currency markets.

Showing posts with label David Miller. Show all posts
Showing posts with label David Miller. Show all posts
Wednesday, September 19, 2007

Pink slips at the FDA will equate to red ink for biotech investors

›
David Miller Andy von Eschenbach, FDA Commissioner, says he’ll have to issue 2,000 60-day pink slips at the FDA if Congress and the Presiden...
Saturday, April 21, 2007

Neurochem (NRMX)

›
David Miller Keep an eye out on Neurochem ( NRMX ) today. The option prices have been very high on this one because it has become yet anoth...
Tuesday, February 20, 2007

Margin Rules Might Make Development Stage Biotech Financials Matter

›
David Miller February 20, 2007 For development-stage biotechnology companies, quarter-to-quarter revenues don’t matter much because these f...
Wednesday, February 7, 2007

BioMarin Pharmaceuticals (BMRN)

›
David Miller February 7, 2007 At the end of this month, BioMarin Pharmaceuticals (BMRN) will report data from a pilot study on uncontrolled ...
›
Home
View web version
Powered by Blogger.